Induced pluripotent stem cells (iPSC) created from skin fibroblasts of patients with Prader-Willi syndrome (PWS) retain the molecular signature of PWS

Stem Cell Research

Volumn 17, Issue 3, 2016, Pages 526-530

  Burnett, Lisa C ^a,b   LeDuc, Charles A ^a,b,c   Sulsona, Carlos R ^d   Paull, Daniel ^e   Eddiry, Sanaa ^f   Levy, Brynn ^a   Salles, Jean Pierre ^f,g   Tauber, Maithe ^f,g,h   Driscoll, Daniel J ^d   Egli, Dieter ^a,b,e   Leibel, Rudolph L ^a,b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Department of Medicine   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e New York Stem Cell Foundation Laboratory   (United States)

^f University of Toulouse III   (France)

^g HÔPITAL DES ENFANTS   (France)

^h French Reference Centre for Prader Willi Syndrome   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NDN PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL; CELL DIFFERENTIATION; CELL LINE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOLOGY; DNA METHYLATION; FIBROBLAST; GENE DOSAGE; GENETICS; GENOTYPE; HUMAN; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOUSE; NERVE CELL; NONOBESE DIABETIC MOUSE; NUCLEAR REPROGRAMMING; PATHOLOGY; PRADER WILLI SYNDROME; SKIN; TERATOMA; TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELLULAR REPROGRAMMING; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; FIBROBLASTS; GENE DOSAGE; GENOTYPE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MICE, INBRED NOD; NEURONS; PRADER-WILLI SYNDROME; SKIN; SNRNP CORE PROTEINS; TERATOMA; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 85008359531     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2016.08.008     Document Type: Article

References (13)

1. Angulo, M.A., Butler, M.G., Cataletto, M.E., Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J. Endocrinol. Investig. 38 (2015), 1249–1263.
2. Bieth, E., et al. Highly restricted deletion of the SNORD116 region is implicated in Prader-Willi syndrome. Eur. J. Hum. Genet. 23 (2015), 252–255.
3. Butler, M.G., Lee, P.D.K., Whitman, B.Y., Management of Prader-Willi Syndrome. 3rd ed., 2006, Springer Science Business Media, Inc., New York.
4. Cassidy, S.B., Driscoll, D.J., Prader–Willi syndrome. Eur. J. Hum. Genet. 17 (2009), 3–13.
5. Chamberlain, S.J., et al. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader–Willi syndromes. Proc. Natl. Acad. Sci. 107 (2010), 17668–17673.
6. Chambers, S.M., et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27 (2009), 275–280.
7. Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., Hasegawa, M., Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B 85 (2009), 348–362.
8. Noggle, S., et al. Human oocytes reprogram somatic cells to a pluripotent state. Nature 478 (2011), 70–75.
9. Sagi, I., et al. Derivation and differentiation of haploid human embryonic stem cells. Nature, 2016.
10. Smith, A., et al. Birth prevalence of Prader-Willi syndrome in Australia. Arch. Dis. Child. 88 (2003), 263–264.
11. Stelzer, Y., Sagi, I., Yanuka, O., Eiges, R., Benvenisty, N., The noncoding RNA IPW regulates the imprinted DLK1-DIO3 locus in an induced pluripotent stem cell model of Prader-Willi syndrome. Nat. Genet. 46 (2014), 551–557.
12. Takahashi, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
13. Yang, J., et al. Induced pluripotent stem cells can be used to model the genomic imprinting disorder Prader-Willi syndrome. J. Biol. Chem. 285 (2010), 40303–40311.